本研究旨在评估高危和寡转移前列腺癌患者的围手术期并发症和肿瘤学结果。对2012年1月至2022年3月期间在作者诊所接受前列腺癌手术的患者数据进行回顾性分析。根据D'amico分类，28名高危前列腺癌患者和23名寡转移期患者纳入研究。患者被分为两组：第 1 组（高危前列腺癌）和第 2 组（少转移癌）。记录患者的人口学特征、肿瘤学数据、病理学数据和并发症。患者的平均年龄为67.84岁（范围52-79岁）。第 1 组的平均随访时间为 45.48 个月，第 2 组的平均随访时间为 46.36 个月 (p = 0.84)。第 1 组的平均血红蛋白下降为 1.53 g/dL，第 2 组的平均血红蛋白下降为 0.69 g/dL (p = 0.046)。第 1 组中的 5 名患者 (17.8%) 在 14.55 个月时出现生化复发，而第 2 组中的 3 名患者 (13%) 在 9.87 个月时出现生化复发 (p = 0.646)。根据 Clavien-Dindo 分类，第 1 组患者中有 7.2% 出现严重并发症，第 2 组患者中有 8.6% 出现严重并发症。 6 名第 1 组患者 (21.4%) 和 12 名第 2 组患者 (52.2%) 检测到手术切缘阳性 (p = 0.023)。随访期间，四名患者死亡。只有一名患者死于癌症。作者认为寡转移和高风险前列腺癌手术在并发症方面没有显着差异。© 2024。外科肿瘤学会。

This study aimed to evaluate perioperative complications and oncologic results for high-risk and oligometastatic prostate cancer patients.The data of patients who underwent surgery for prostate cancer in the authors' clinic between January 2012 and March 2022 were analyzed retrospectively. According to D'amico classification, 28 patients with high-risk prostate cancer and 23 patients in the oligometastatic stage were included in the study. The patients were divided into two groups: group 1 (high-risk prostate cancers) and group 2 (oligometastatic cancer). Demographic characteristics, oncologic data, pathologic data, and complications of the patients were recorded.The mean age of the patients was 67.84 years (range, 52-79 years). The average follow-up period was 45.48 months for group 1 and 46.36 months for group 2 (p = 0.84). The mean hemoglobin decrease was 1.53 g/dL in group 1 and 0.69 g/dL in group 2 (p = 0.046). Five patients (17.8%) in group 1 had biochemical recurrence at 14.55 months, whereas three patients (13%) in group 2 had biochemical recurrence at 9.87 months (p = 0.646). According to Clavien-Dindo classification, major complications developed in 7.2% of the group 1 patients and in 8.6% of the group 2 patients. Surgical margin positivity was detected in 6 group 1 patients (21.4%) and 12 group 2 patients (52.2%) (p = 0.023). During the follow-up period, four patients died. Only one of the patients died of cancer.The authors think that oligometastatic and high-risk prostate cancer surgeries do not differ significantly in terms of complications.© 2024. Society of Surgical Oncology.